Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
← catalyst calendarNCT04614103 · readout ≤ 1,594 d
Sponsored by Iovance Biotherapeutics, Inc. (industry) · IOVA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
170estimated
Sites
71
Countries
Australia, Canada, France +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-07 | actual | When the study began enrolling |
| Primary completion | Dec 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Non Small Cell Lung Cancer
Interventions
- Biological: LN-145 — also filed as TIL, Autologous Tumor Infiltrating Lymphocytes
- Biological: LN-145 — also filed as TIL, Autologous Tumor Infiltrating Lymphocytes
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate
measured Up to 60 months
Permalink · IOVA's whole pipeline · Catalyst calendar · Every registered study · What changed